muramidase and Hepatitis-B

In a study designed to determine the preventive effect of lysozyme on post-transfusion hepatitis, 260 patients with orthopedic diseases, who received blood by transfusion during a period of 5 years from June 1970 to May 1975, were divided at random into a group of 123 patients treated with lysozyme is doses of 60 to 170 mg/day for 4 to 24 weeks, and a control group of 137 patients. The incidence of post-transfusion hepatitis was 10 (8.1%) out of 123 patients for the treated group, and 28 (20.4%) out of 137 patients for the control group. Icteric hepatitis occurred in 1 (0.8%) patient in the treated group, while its incidence in the control group was 8 (5.8%) out of 137 patients.

Topics: Adult; Aged; Clinical Trials as Topic; Female; Hepatitis B; Humans; Male; Middle Aged; Muramidase; Random Allocation; Transfusion Reaction

The aim of the study, was to evaluate the excretion of amylase, lysozyme and beta 2 microglobulin (B2-M) in patients with acute and chronic virus B hepatitis. The gathered findings show the maintained ability of tubules cells to reabsorption lysozyme and B2-M. The elevated excretion of amylase in the urine of patients with acute viral hepatitis show the transient decrease of abilities to absorb this enzyme by teh cells of the tubules. It may be caused by the saturation of the catabolic mechanism of the proteins in tubule cells as well as the decrease of their energetic abilities due to toxic activity of bilirubin and bile acids.

Topics: Adult; Amylases; beta 2-Microglobulin; Hepatitis B; Humans; Kidney Tubules; Middle Aged; Muramidase

Topics: Adolescent; Age Factors; Child; Complement C3; Complement System Proteins; Hepatitis A; Hepatitis B; Humans; Muramidase

Topics: Chronic Disease; Hepatitis B; Humans; Muramidase; Time Factors

Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Hepatitis B; Humans; Middle Aged; Muramidase; Prednisolone